Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aoxing and Johnson Matthey Announce China JV for Narcotic APIs

publication date: Apr 27, 2010
Aoxing Pharmaceutical Company and Johnson Matthey Plc of the UK agreed to set up a JV to develop APIs for narcotic and neurological drugs. The two companies plan to invest $15 million in the new entity over the next five years. An Aoxing subsidiary will own 51% of the venture, while Macfarlan Smith (Hong Kong), an affiliate of Johnson Matthey Pacific Ltd., will hold the remaining 49%. The goal is to produce APIs for the China market. More details...

Stock Symbol: (AMEX: AXN)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital